Dare Bioscience (NASDAQ:DARE) and aTyr Pharma (NASDAQ:ATYR) Head to Head Analysis

Dare Bioscience (NASDAQ:DARE) and aTyr Pharma (NASDAQ:ATYR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability and analyst recommendations.

Insider and Institutional Ownership

6.7% of Dare Bioscience shares are held by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are held by institutional investors. 4.8% of Dare Bioscience shares are held by company insiders. Comparatively, 5.8% of aTyr Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Dare Bioscience and aTyr Pharma”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dare Bioscience	$1.03 million	33.08	-$13.40 million	($1.25)	-1.87
aTyr Pharma	$190,000.00	430.13	-$74.12 million	($0.79)	-1.06

Dare Bioscience has higher revenue and earnings than aTyr Pharma. Dare Bioscience is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings for Dare Bioscience and aTyr Pharma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dare Bioscience	1	0	2	0	2.33
aTyr Pharma	1	5	1	0	2.00

Dare Bioscience presently has a consensus target price of $10.00, suggesting a potential upside of 327.35%. aTyr Pharma has a consensus target price of $25.67, suggesting a potential upside of 2,979.38%. Given aTyr Pharma’s higher probable upside, analysts plainly believe aTyr Pharma is more favorable than Dare Bioscience.

Profitability

This table compares Dare Bioscience and aTyr Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Dare Bioscience	N/A	N/A	-56.52%
aTyr Pharma	N/A	-99.87%	-74.41%

Risk & Volatility

Dare Bioscience has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. Comparatively, aTyr Pharma has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500.

Summary

Dare Bioscience beats aTyr Pharma on 7 of the 13 factors compared between the two stocks.

About Dare Bioscience

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

About aTyr Pharma

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.